Table 1 Summary of key inclusion... | American Society of Hematology

Table 1

Summary of key inclusion criteria and TKI retreatment triggers used in clinical trials

Study	TKI	Number of patients reported	Required depth of MR	Minimum duration of MR (years)	Trigger to resume TKI
STIM²⁰	Imatinib (±prior IFN)	100	UMRD (MR5.0)	2	Loss of UMRD*
TWISTER²¹	Imatinib (±prior IFN)	40	UMRD (MR4.5)	2	Loss of UMRD
A-STIM²²	Imatinib (±prior IFN)	80	UMRD†	2	Loss of MMR
EuroSKI²⁴	Imatinib/nilotinib/dasatinib	200	MR4.0	1	Loss of MMR
Stop 2GTKI²⁸	Nilotinib/dasatinib first and second line	52	UMRD (MR4.5)	2	Loss of MMR
KIDS²⁵	Imatinib (±prior IFN)	90	UMRD (MR4.5)	2	Loss of MMR
HOVON³²	Imatinib	18	UMRD (MR4.5)	2	Loss of UMRD
DADI²⁷	Second-line dasatinib	63	MR4.0	1	Loss of MR4.0
STIM2²⁶	Imatinib	124	UMRD (MR4.5)	2	Loss of UMRD

Study	TKI	Number of patients reported	Required depth of MR	Minimum duration of MR (years)	Trigger to resume TKI
STIM²⁰	Imatinib (±prior IFN)	100	UMRD (MR5.0)	2	Loss of UMRD*
TWISTER²¹	Imatinib (±prior IFN)	40	UMRD (MR4.5)	2	Loss of UMRD
A-STIM²²	Imatinib (±prior IFN)	80	UMRD†	2	Loss of MMR
EuroSKI²⁴	Imatinib/nilotinib/dasatinib	200	MR4.0	1	Loss of MMR
Stop 2GTKI²⁸	Nilotinib/dasatinib first and second line	52	UMRD (MR4.5)	2	Loss of MMR
KIDS²⁵	Imatinib (±prior IFN)	90	UMRD (MR4.5)	2	Loss of MMR
HOVON³²	Imatinib	18	UMRD (MR4.5)	2	Loss of UMRD
DADI²⁷	Second-line dasatinib	63	MR4.0	1	Loss of MR4.0
STIM2²⁶	Imatinib	124	UMRD (MR4.5)	2	Loss of UMRD

DADI, Dasatinib Discontinuation study; HOVON, Stichting Hemato-Oncologie voor Volwassenen Nederland.

A-STIM allowed occasional low level positive RQ-PCR results during the 2 years of UMRD.

†

Loss of UMRD in STIM and STIM2 was defined as ≥2 consecutive samples with detectable BCR-ABL and a 1-log increase; in TWISTER and the HOVON study, any 2 consecutive samples at any level were considered loss of UMRD.

View Large

This Feature Is Available To Subscribers Only